Methods of selectively treating asthma using IL-17 antagonists

US10676522B2 · kind B2 · utility

Assignee

• Novartis AG · CH

Inventors

• Sarah Grant · Boston, US
• Shamsah Kazani · Watertown, US
• Edward Khokhlovich · Newton, US
• Jason Laramie · Westwood, US
• Robert M. Strieter · Ann Arbor, US
• Tricia Ann Thornton-Wells · Lincoln, US

Key dates

• Filing date: May 3, 2018
• Grant date: Jun 9, 2020
• Expiry date: May 3, 2038

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2800/52
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The disclosure relates to methods, treatment regimens, uses, kits and therapies for treating asthma, such as severe asthma, by employing IL-17 antagonists to a patient population defined by serum concentration of IgE and optionally also an eosinophil count in peripheral blood.